Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 4 1Phase 3 1

Status

Completed 13Terminated 10Active not recruiting 8Recruiting 6Unknown 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 41Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Mantle-Cell 20Lymphoma, Follicular 18Lymphoma 17Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, B-Cell 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 3Leukemia 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Heart Failure 2Epstein-Barr Virus Infections 2Dendritic Cell Sarcoma, Interdigitating 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Thalassemia 1Sjogren's Syndrome 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Rituximab × Clear all
NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCOREâ„¢FL-2

Genmab

Phase 3 Recruiting
1,095 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05099471 2026-05-05

VIWA-1

University of Ulm

Phase 2 Recruiting
80 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
37 enrolled

Neoplasms, Recurrence

NCT05615974 2024-12-19

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

LaNova Medicines Limited

Phase 1/2 Recruiting
139 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡